文献速递临床试验与 GCP

心房颤动导管消融与药物治疗及心理困扰:一项随机临床试验

Atrial Fibrillation Catheter Ablation vs Medical Therapy and Psychological Distress: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2023-01-01

REMEDIAL随机试验在澳大利亚2个房颤中心纳入100例有症状的房颤患者,比较导管消融(52例)与单纯药物治疗(48例)对心理困扰的影响。12个月时消融组HADS总分低于药物组(7.6 vs 11.8,组间差-4.17,95%CI -7.04至-1.31,P=.005),严重心理困扰比例、焦虑、抑郁及BDI-II评分在多个随访点均较低。

要点

  • 12个月时消融组HADS总分7.6 vs 药物组11.8,组间差-4.17(95%CI -7.04至-1.31,P=.005)。
  • 12个月严重心理困扰比例消融组10.2% vs 药物组31.9%(P=.01)。
  • 消融组房颤负荷中位数0%(IQR 0%-3.22%)低于药物组15.5%(IQR 1.0%-45.9%)(P<.001)。

核心结论

  • 在有症状的房颤患者中,导管消融可改善焦虑和抑郁心理症状,而药物治疗未观察到类似改善。

研究设计与样本

  • REMEDIAL研究是一项随机试验,在澳大利亚2个房颤中心于2018年6月至2021年3月纳入有症状的房颤患者。
  • 共100例参与者随机接受房颤导管消融(n=52)或药物治疗(n=48)。
  • 参与者平均年龄59(12)岁,女性31例(32%),阵发性房颤占54%。

主要发现

  • 消融组所有参与者均成功实现肺静脉隔离。
  • 6个月时消融组HADS总分8.2(5.4) vs 药物组11.9(7.2)(P=.006);12个月时消融组7.6(5.3) vs 药物组11.8(8.6),组间差-4.17(95%CI -7.04至-1.31)(P=.005)。
  • 6个月严重心理困扰(HADS>15)比例消融组14.2% vs 药物组34%(P=.02);12个月消融组10.2% vs 药物组31.9%(P=.01)。
  • 焦虑HADS评分6个月消融组4.7(3.2) vs 药物组6.4(3.9)(P=.02),12个月消融组4.5(3.3) vs 药物组6.6(4.8)(P=.02);抑郁HADS评分3个月消融组3.7(2.6) vs 药物组5.2(4.0)(P=.047),6个月消融组3.4(2.7) vs 药物组5.5(3.9)(P=.004),12个月消融组3.1(2.6) vs 药物组5.2(3.9)(P=.004)。
  • BDI-II评分6个月消融组7.2(6.1) vs 药物组11.5(9.0)(P=.01),12个月消融组6.6(7.2) vs 药物组10.9(8.2)(P=.01);消融组房颤负荷中位数0%(IQR 0%-3.22%)低于药物组15.5%(IQR 1.0%-45.9%)(P<.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The impact of atrial fibrillation (AF) catheter ablation on mental health outcomes is not well understood. OBJECTIVE: To determine whether AF catheter ablation is associated with greater improvements in markers of psychological distress compared with medical therapy alone. DESIGN, SETTING, AND PARTICIPANTS: The Randomized Evaluation of the Impact of Catheter Ablation on Psychological Distress in Atrial Fibrillation (REMEDIAL) study was a randomized trial of symptomatic participants conducted in 2 AF centers in Australia between June 2018 and March 2021. INTERVENTIONS: Participants were randomized to receive AF catheter ablation (n = 52) or medical therapy (n = 48). MAIN OUTCOMES AND MEASURES: The primary outcome was Hospital Anxiety and Depression Scale (HADS) score at 12 months. Secondary outcomes included follow-up assessments of prevalence of severe psychological distress (HADS score >15), anxiety HADS score, depression HADS score, and Beck Depression Inventory-II (BDI-II) score. Arrhythmia recurrence and AF burden data were also analyzed. RESULTS: A total of 100 participants were randomized (mean age, 59 [12] years; 31 [32%] women; 54% with paroxysmal AF). Successful pulmonary vein isolation was achieved in all participants in the ablation group. The combined HADS score was lower in the ablation group vs the medical group at 6 months (8.2 [5.4] vs 11.9 [7.2]; P = .006) and at 12 months (7.6 [5.3] vs 11.8 [8.6]; between-group difference, -4.17 [95% CI, -7.04 to -1.31]; P = .005). Similarly, the prevalence of severe psychological distress was lower in the ablation group vs the medical therapy group at 6 months (14.2% vs 34%; P = .02) and at 12 months (10.2% vs 31.9%; P = .01), as was the anxiety HADS score at 6 months (4.7 [3.2] vs 6.4 [3.9]; P = .02) and 12 months (4.5 [3.3] vs 6.6 [4.8]; P = .02); the depression HADS score at 3 months (3.7 [2.6] vs 5.2 [4.0]; P = .047), 6 months (3.4 [2.7] vs 5.5 [3.9]; P = .004), and 12 months (3.1 [2.6] vs 5.2 [3.9]; P = .004); and the BDI-II score at 6 months (7.2 [6.1] vs 11.5 [9.0]; P = .01) and 12 months (6.6 [7.2] vs 10.9 [8.2]; P = .01). The median (IQR) AF burden in the ablation group was lower than in the medical therapy group (0% [0%-3.22%] vs 15.5% [1.0%-45.9%]; P < .001). CONCLUSION AND RELEVANCE: In this trial of participants with symptomatic AF, improvement in psychological symptoms of anxiety and depression was observed with catheter ablation, but not medical therapy. TRIAL REGISTRATION: ANZCTR Identifier: ACTRN12618000062224.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Al-Kaisey AM, Parameswaran R, Bryant C, et al. Atrial Fibrillation Catheter Ablation vs Medical Therapy and Psychological Distress: A Randomized Clinical Trial. JAMA. 2023. PMID: 37698564. doi:10.1001/jama.2023.14685

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。